Global X Reports 5.08% Of Oklo — Its Managed Funds Receive The Proceeds

The investment adviser reported 9,907,787 shares as Oklo finances reactor deployments and secures fuel supplies.

Share
Global X Reports 5.08% Of Oklo — Its Managed Funds Receive The Proceeds

Global X Management, an investment adviser, reported a 5.08% holding in Oklo, which develops nuclear power plants, in a passive ownership disclosure filed Monday. The position totaled 9,907,787 Class A shares as of September 30.

The Funds' Economic Rights

Investment companies managed by Global X have the rights to dividends and proceeds from sales of the reported shares. Global X reported sole voting authority over the entire position.

The adviser certified that it bought and holds the securities through its ordinary business activities, without a purpose of changing or influencing Oklo's control.

Stock Sales And Reactor Fuel

Oklo raised approximately $2.3 billion through stock sales during the first nine months to finance its reactor plans. Its market value was $4.7 billion as of Monday at 8:11 p.m. ET.

Oklo signed definitive agreements Thursday with Centrus Energy for multiple years of fuel supplies covering up to five Aurora powerhouses. The contracts put a June 2026 letter of intent into binding agreements.

Meta is paying ahead for future electricity to help fund those purchases. Its initial installment went directly to Centrus following its release from escrow on November 2.

Oklo intends to use the fuel in its initial Ohio deployments, future Aurora projects and refueling of its first Idaho reactor.

Selling Energy From Aurora Plants

Oklo's plan is to own and run Aurora powerhouses, producing electricity and heat and selling energy directly under power purchase agreements. Its prospective customers include data centers, industrial businesses, government facilities, remote communities and utilities.

The company also develops used-fuel recycling and fuel-fabrication technology. Its Atomic Alchemy subsidiary works on radioisotope production for medical, research and other uses.

Sources